

New Progress Regarding the Use of Lactic Acid Bacteria as Live Delivery Vectors, Treatment of Diseases and Induction of Immune Responses in Different Host Species Focusing on *Lactobacillus* Species

Seria Masole Shonyela^{1,2}, Guan Wang², Wentao Yang², Guilian Yang¹ and Chun Feng Wang^{1*}

¹Jilin Provincial Engineering Research Center of Animal Probiotics, College of Animal Science and Technology, Jilin Agricultural University, Changchun, PR China

²Ministry of Agriculture, Livestock and Fisheries, Veterinary Complex, Nelson Mandela Road, Dar es Salaam, Tanzania

*Corresponding authors: Chun Feng Wang, Jilin Provincial Engineering Research Center of Animal Probiotics, College of Animal Science and Technology, Jilin Agricultural University, Changchun, PR China, Tel: +86-43184533425; E-mail: wangchunfeng@jlau.edu.cn

Received date: September 29, 2017; Accepted date: October 12, 2017; Published date: October 22, 2017

Copyright: © 2017 Shonyela SM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Lactobacillus species are non-spore-forming, Gram-positive bacteria and lactic acid producing bacteria (LAPB) that naturally inhabits the human and animal gastrointestinal and mouth organs. The aim of this review was to evaluate the new progress regarding the use of *Lactobacillus* species as live delivery vectors, prevention and treatment of pathogenic and metabolic diseases. *Lactobacillus* strains as probiotics have been extensively studied and have confirmed that they can absolutely improve performance as live delivery vectors, a treatment option of various diseases such as: hemorrhagic cecal coccidiosis in young poultry, Hypertension, avian flu, obesity, diabetes, Derzsy's disease or parvovirus infection, human immunodeficiency virus infections, irritable bowel syndrome, gastrointestinal disorders, Fungal infections, vaginal eubiosis, fish and shellfish species diseases.

We give you an idea about that *Lactobacillus* species have been proficient in preventing and treating both disorders in animal models and some used for clinical trials. We present the most current studies on the use of *Lactobacillus* strains that had an impact on an effective immune response to a specific antigen because a variety of antigens have been expressed. Therefore *Lactobacillus* strains can be considered as good candidates because of its potential for diseases treatment and vaccine development as heterologous protein secretion to date.

Keywords: *Lactobacilli*; Probiotics; Lactic acid; Live delivery vectors; Treatment; Immune responses

Introduction

Lactic acid bacteria (LAB) are Gram-positive bacteria, nonpathogenic they are considered to be generally regarded as safe (GRAS) organisms [1,2]. Daily ingested by humans playing significant point, to improve general health and protect from different kinds of illness [3-6]. Also used as production of food and feed throughout the world [7-11] because widely used in the food industry for the production and the preservation of fermented products such as whole-grain sourdough bread or sourdough fermentation [12,13]. Daily consumption of dairy yogurt having *Lactobacillus paracasei*, and heat-treated *Lactobacillus plantarum* possibly is successful alternative to improve immune function by enhancing IFN- γ concentration and NK cell function [14]. Probiotics can also survive on non-dairy foods under ambient storage conditions [15].

Recent studies presents that *Lactobacillus* species have been used as Probiotics for the prevention or treatment of a range of diseases associated to diarrhea [16-18]. *Lactobacillus plantarum* assimilate cholesterol and modulate ABCA1, CD36, NPC1L1 and SCARB1 *in vitro* [19], Immune function [20], Inflammatory bowel disease [21-23], Respiratory viral infection [24]. In addition, probiotic bacteria in the *Lactobacillus* genera are capable to have therapeutic effects in the patients of psychological disorders, such as depression, anxiety, and memory [25-27].

The move towards for controlling the immune hyper-response in today's situation for the most part appoints the natural ways which assist the body to uphold the immune homeostasis and do not cause any side effects [28], such as use of probiotics in the company of combination of a non-digestible food ingredient that promotes the growth of beneficial microorganisms in the intestines. Quite a lot of research projects have used *Lactobacillus* strains as vectors including our laboratory (Jilin Provincial Engineering Research Center of Animal Probiotics) and other probiotics research projects in the world [29-35]. In addition *Lactobacillus* strains are well thought-out to be competent candidates for delivery systems of heterologous proteins and for the development of novel, safe production [36].

In this review, we evaluate the new progress regarding the use of *Lactobacillus* strains as live delivery vectors. An assortment of molecular tools has been developed to professionally express therapeutic molecules and antigens at different cellular localizations. We report systems developed to use *Lactobacillus* strains as a live vaccine, treatments and the effects of such an antigen presentation mode on both systemic and mucosal immune system.

Lactobacillus strains as health promoting probiotics

Lactobacillus species are non-spore-forming Gram-positive bacteria and lactic acid producing bacteria (LAPB) that naturally inhabits the human and animal gastrointestinal and mouth organs [37-39]. Many genetic tools have been developed and many of *L.* species its complete genome were recently sequenced [20,37,40-42]. *Lactobacillus* species have met the criteria necessary to consider them as probiotics and they

also have nutritional and therapeutic effects, regarded as probiotics because they are able to survive and thrive throughout the gastrointestinal conditions and present their beneficial effects. It is therefore important to understand their mechanisms of action in order for them to be used both prophylactic and as treatment options for different diseases [41-43]. *Lactobacillus* species are an important part of normal intestinal microbiota of various mammalian species and is also the best characterized and widely commercialized probiotic because they provide an affordable means for prevention and treatment of various infectious, allergic and inflammatory conditions as demonstrated in numerous animal and human studies [44,45]. The *in vitro* study by [46] about comparing Antibacterial activity of *Lactobacillus plantarum* Strains (Os13 and Kor14) showed strong antimicrobial activities against a wide range of potential pathogens especially *L. monocytogenes* since were active against potential pathogens and each *Lactobacillus plantarum* strains produced broad spectrum of antimicrobial agents. However, it is known that the health-promoting properties of *Lactobacillus* strains probiotics change extensively in response to their culture conditions. This is because may results in profound variability in probiotic functionality even when the strain remains unchanged, such as the IL-10 and IL-12 modulatory activity of *L. plantarum* OLL2712 changes according to culture conditions [22].

Management of gastrointestinal disorders

In probiotic aspects, *Lactobacillus* species confirmed helpful roles in the commencement of the gut mucosal immune system [47,48]. Supplementation with specific strains of *Lactobacillus* species as probiotics has been revealed to have modulatory effects on intestinal [1,49-52]. Efficient expression systems have already been developed for controlled and targeted production of the desired antigen for exposure to the gastrointestinal mucosal immune system [53-55] as have been shown to provide beneficial health effects to the host by replenishing natural gastrointestinal flora. *In vitro* studies have shown that *Lactobacillus* species supplementation protected the pigs against ETEC K88 infection by enhancing immune responses which attenuated intestinal damage, improved the performance and nutrient digestibility of pigs [43]. Also *Lactobacillus reuteri* I5007 strain modulated intestinal host defense peptides (HDP) expression and improved the gut health of neonatal piglets [56].

The study by Olek showed that there was no statistically significant differences between the *Lactobacillus plantarum* DSM 9843 (LP299V) and placebo groups in the prevention of antibiotic-associated gastrointestinal symptoms in children and reduced the incidence of diarrhea [57]. The study about the use of fermented dairy drink containing probiotic *Lactobacillus paracasei* CNCM I-1518 to prevent Antibiotic-associated diarrhea showed the importance of *Lactobacillus* strains in improving health [58]. Also older hospitalized patients treated with antibiotics lead to considerable cost savings, in addition to Infants hospitalized with rotavirus disease were treated with probiotics containing both *Bifidobacterium longum* BORI and *Lactobacillus acidophilus* AD031, Symptoms such as duration of fever, frequency of diarrhea, and frequency of vomiting tended to be ameliorated by the probiotic treatment [59].

Lactobacillus johnsonii could decrease intestinal *Campylobacter jejuni* burdens as offer valuable prophylaxis and treatment of *C. jejuni* induced intestinal, pro-inflammatory immune responses *in vivo* [60] and systemic immune responses in animal models and forms the basis for animal and human studies with vaccines [49-51,61]. The study of *in*

vitro and *in vivo* antagonistic activity of new probiotic culture against *Clostridium difficile* and *Clostridium perfringens*, exhibited immunomodulatory activity and among hospitalized adults, *Lactobacillus* probiotics reduced the risk of *Clostridium difficile*-associated diarrhea when taken concomitantly with antibiotics, with no evident increase in adverse events [62,63]. Although it shown that in elderly orthogeriatric patients on antibiotic do not support the use of Probiotic containing *Lactobacillus casei*, *Lactobacillus bulgaricus*, and *Streptococcus thermophiles* (ACTIMEL) for reducing the incidence of *Clostridium difficile* associated diarrhoea (CDAD). Regardless of these patients being at high risk for developing CDAD, failure to reveal a significant advantage makes this infection control strategy difficult to give good reason for [64]. Some studies have revealed that they give a helpful effect by production of antimicrobial molecules and promoting secretion of immunoglobulin IgA which are capable of inhibiting some intestinal pathogens [65,66]. Evaluation of *Lactobacillus reuteri* L26 was concluded that has an antiviral effect on PCV2 in the intestine as immune response against porcine circovirus type 2 infections in germ-free mice significantly up-regulated gene expression of chemokines, interferon (IFN)- γ , IgA and PIgR in the ileum was accompanied by higher proportion of natural killer cells and higher proportion of CD19+lymphocytes in the MLN [67].

Prevention and management of hypertension

Several animal and human studies have observed the association between the oral and gut microbiome with blood pressure [68]. The study confirmed a considerable reduction in microbial richness and multiplicity in the presence of hypertension. As well studies have confirmed a changed microbial composition and modified metabolite profiles, suggesting a role for microbial dysbiosis and microbial metabolites which including use of *Lactobacillus* species for hypertension treatment [66,69,70]. Some studies showed the effectiveness and safety of *Lactobacillus* species on the treatment of hypertension. As were observed in hypertensive patients increased myeloid inflammatory cells CD14+cells, CD11b+cells and Th17 cells, increased in CD4+IL17+cells. An increase in the Th17 cells was tremendously appropriate finding because demonstrated that levels of these cells were regulated by gut-intrinsic mechanisms that generate pro-inflammatory cytokines for instance TGF- β 1, TNF- α , IL-1 β and IL-6 [71-73].

Oral administration of recombinant *Lactobacillus plantarum* NC8 considerably decreased systolic blood pressure, increased level of nitric oxide, as well as decreased levels of endothelin and AngII in plasma, heart, and kidney, representing the potential application of recombinant *Lactobacillus plantarum* in the treatment of hypertension [69]. In additional; an oral, genetically-modified strain of the probiotic *Lactobacillus* was used to treat rats with high blood pressure in the lungs, which resulted in improved heart contractility, reduced blood pressure, and reduced heart wall thickness. Also researchers genetically engineered strains of *Lactobacillus* species, to express and secrete Ang-(1-7), tested in an animal study and was effectively treat pulmonary hypertension [69]. Fermented whey from bovine milk with several *Lactobacillus* species to free antihypertensive peptides from whey, and found that *Lactobacillus helveticus* fermented whey hydrolysates contained peptides which showed strong angiotensin 1-converting enzyme inhibition. These peptides, at least in part, contributed to the ACE inhibitor effect of the fermentate. Whey fermented with *Lactobacillus brevis* also contained a potent ACE inhibitor peptide [74].

Prevention and management of respiratory tract disorders

The studies in the infant mice and immunocompromised-malnourished mice showed the improvement of the resistance to primary respiratory syncytial virus (RSV) infection, and secondary pneumococcal pneumonia. In relationship with the protection against RSV-pneumococcal superinfection, the study revealed that peptidoglycan from *Lactobacillus rhamnosus* CRL1505. Considerably enhanced lung CD3+CD4+IFN- γ +, and CD3+CD4+IL-10+ T cells plus CD11c+Sigle cF+IFN- β +alveolar macrophages with the resulting of increases of IFN- γ , IL-10, and IFN- β in the respiratory tract [75,76]. Nasal administration of *Lactobacillus rhamnosus* CRL1505 strain to malnourished mice under recovery reduced quantitative and qualitative alterations of CD4+T cells in the bone marrow, thymus, spleen and lung as well, CRL1505 treatment increased Th2-cytokines; interleukin 10 and 4 in respiratory and systemic compartments [77]. The study of immunization with recombinant *Lactobacillus plantarum* expressing 3M2e-Fc demonstrated the markedly reduction of the viral load in the lung and protected against H1N1 influenza virus. As well as mouse-adapted H9N2 avian influenza virus (AIV) challenge in BALB/c mice, also provided effective protective immunity against infection with homologous and heterologous influenza viruses in a mouse mode and were seem to lower respiratory tract infections [29,78]. The study of the effect of a probiotic supplement on the incidence of upper respiratory tract infections [61], and the metabolism of aromatic amino acids after exhaustive aerobic exercise in trained athletes daily supplementation with probiotics was found to be associated with a lower frequency of URTIs in athletes and seems to be beneficial in increasing training efficacy [79]. Respiratory viral infection via metabolic reprogramming and immune cell modulation by *Lactobacillus johnsonii* [24], Avian Influenza infection [34,80,81]. In additional *Lactobacillus plantarum* GBLP2 isolated from Korean fermented vegetable exhibited preventive effect against the influenza virus infections in mice [82].

Management of chronic constipation

Differentiations in the composition of the intestinal microbiota have been confirmed when constipated patients and healthy controls have been evaluated in different studies and have shown that *Lactobacillus* may play an essential role in the pathogenesis of chronic constipation [83]. *Lactobacillus* species as probiotics could reduce the migrating myoelectric complex (MMC) period and speed up small intestinal transit. Especially some of a good number studied strains such as *Lactobacillus casei*, *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, showed a significant role of reducing the level of intraluminal pH and promoting colonic peristalsis which is supportive for changing stool that could significantly increase the frequency of defecations and the softness of the stool [84-86]. The assessment of the effectiveness of *Lactobacillus casei rhamnosus* Lcr35 (Lcr35) in the management of functional constipation in children showed a significant increase in the frequency of defecation in both the placebo group and in the *Lactobacillus casei rhamnosus* Lcr35 group [87].

Prevention and management of hypercholesterolaemia

Recent studies have shown the potential use of *Lactobacillus* species as part of the strategies in prevention and management of hypercholesterolaemia. Eating yogurt or taking capsules containing the *Lactobacillus* strain for example *Lactobacillus reuteri* NCIMB 30242 give the impression to decrease low-density lipoprotein cholesterol in adults with high cholesterol. Furthermore treatment of HT29 cells with

Lactobacillus plantarum after prolonged exposure to cholesterol source it was demonstrated that was associated with up-regulation of ABCA1, restoration of CD36 to basal level and down-regulation of Neimann-Pick C1-Like 1 (NPC1L1). Also *Lactobacillus fermentum* NCIMB 5221 and *Lactobacillus fermentum* NCIMB 2797 have the potential via various modes of action to lower cholesterol [88-90].

Enhancement of anti-inflammatory response

Lactobacillus plantarum L9 and *Lactobacillus acidophilus* LA were shown to some studies that have significant inhibition of *E. coli* adhesion and cell internalization to the enterocyte monolayer surface. Such as the study by [91] made known that *Lactobacillus plantarum* L9 and *Lactobacillus acidophilus* LA have good ability to adhere to Caco-2 cells. As well treatment with mixed lactic acid bacteria increased the anti-inflammatory factor and the secretion of sIgA in the intestine of mice infected with *Staphylococcus aureus* inhibited the inflammation [45,92-95]. *Lactobacillus fermentum* HY01 strain in some studies showed that had significant preventive effects in dextran sulfate sodium induced-colitis; at the same time, it can efficiently reduce edema, inflammatory cells infiltration, and colon mucosa injury. In addition to play a significant function in the down-regulation of concentrations of pro-inflammatory factors (IFN-, IL-12, TNF, and IL-6) in particular shows a hopeful prevention for I_B_ degradation, decreases the protein levels of iNOS and COX-2 along with inhibition of NF- κ B p65 phosphorylation cascades [17,96,97]. The outcome from some studies obtained from *Lactobacillus rhamnosus* GG, *Lactobacillus rhamnosus* KLSL, *Lactobacillus helveticus* IMAU70129, and *Lactobacillus casei* IMAU60214 demonstrated that strains induced early proinflammatory cytokines for example IL-8, TNF- α , IL-12p70, IL-6 and IL-1 β . Phagocytosis and bactericidal activity of macrophages against various pathogens, such as *S. aureus*, *S. typhimurium*, and *E. coli*, were increased by pretreatment with *Lactobacillus* [45,98,99].

Management of lactose and glucose intolerance

Population for whom lactose acts like an osmotic, non-digestible carbohydrate for the reason that they have a low amount of intestinal lactase; Lactose intolerance is a problem for a large part of the world. The predigestion of lactose could decrease the symptoms related with lactose intolerance in vulnerable persons. For the duration of fermentation of milk and yogurt having *Lactobacillus acidophilus*, generate lactase that hydrolyses lactose to galactose and glucose. *Lactobacillus* species probiotics have been revealed to improve lactose digestion and intolerance in some studies [100]. Glucose intolerance was to some extent prevented by supplementation of *Lactobacillus kefir* treatment changed Bacteroidetes and Firmicutes profiles. It was demonstrated that the administration of *Lactobacillus kefir* prevents the deleterious effects of fructose-rich diet intake, therefore improved metabolic disorders [101].

Prevention and management of cancer

Lactobacilli Strains play significant function in cancer etiology for the reason that they can manipulate several elements of the intestinal tract such as development, immune homeostasis, physiology and metabolism. Laboratory-based studies have demonstrated that *Lactobacilli* Strains contains strong anti-tumor effects [102]. Many studies of anti-tumor vaccines of *Lactobacillus* species using mouse models have been employed. *Lactobacillus* biotherapeutic for colorectal cancer (CRC), inhibited cancer-causing events, based on anti-CRC proliferative effect, immune modulation and metabolic

activity, *in vitro* and *in vivo*, using a genetically-induced animal CRC model [103]. The study of inhibitory effects of probiotic *Lactobacillus* on the Growth of Human Colonic Carcinoma Cell Line HT-29 showed that *Lactobacillus* can inhibit the growth of colonic carcinoma cells and may lead to apoptosis. Live *Lactobacillus acidophilus* and *Lactobacillus rhamnosus* GG, *Lactobacillus casei*, *Lactobacillus reuteri* has been confirmed to induce apoptotic cell death in both murine and human colon carcinoma cell lines as well as an experimental tumor model [104-108].

Management of diabetes and obesity

Current review study revealed that construction of a recombinant strain of *Lactobacillus gasseri*, *Lactobacillus paracasei* elicits various health benefits through its antimicrobial activity, bacteriocin production, and immunomodulation of the innate and adaptive systems therefore had significantly reduced blood glucose levels and increased insulin levels [109-111]. Also *Lactobacillus* species such as: *Lactobacillus acidophilus*, *Lactobacillus plantarum*, *Lactobacillus paracasei*, *Lactobacillus bulgaricus* have been known to improve obesity-associated metabolic problems. Researchers said this may be attributed to interactions with obesity-promoting bacteria in the gut and direct modulation of host immunity and gut barrier function. Administration of *Lactobacillus johnsonii* N6.2 considerably decreases the happening of indigestion, abdominal pain, and cephalic syndromes were observed. Additionally, some studies demonstrated that monocytes and natural killer cell numbers were increased significantly and an increase of circulating effector Th1 cells (CD45RO +CD183+CD196-) and cytotoxic CD8+T cells subset was observed in the *Lactobacillus johnsonii* N6.2 group [109,112].

Management of irritable bowel syndrome

The thoroughly assessment and a meta-analysis studies of the effect of *Lactobacillus* in treating the irritable bowel syndrome was found to be more effective with a significantly higher rate without any side effects. The researchers noted that abdominal distension was significantly reduced by probiotics containing, *Lactobacillus casei*, or *Lactobacillus plantarum* and flatulence, pain and bloating caused by IBS were significantly reduced by *Lactobacillus acidophilus*, have concluded that some *Lactobacillus* are beneficial in improving symptoms and reducing the risk of persistent symptoms in some patients with Irritable bowel syndrome, even though the overall effect is modest [113-115].

Prevention and management of fungus

Lactobacillus acidophilus DDS-1, *Lactobacillus casei*, *Lactobacillus plantarum*, *Lactobacillus salivarius*, *Lactobacillus rhamnosus*, and *Lactobacillus brevis* are acknowledged to inhibit the growth of *Candida albicans* by enhancing the immune system, reduce the candida overgrowth and by taking repeatedly prevents the reappearance of yeast infections in future [58].

Prevention and management of vaginal infections

Lactobacillus species are thought to be a valuable biomarker and agents that can promote various aspects of vaginal health such as *Lactobacillus crispatus*, *Lactobacillus jensenii*, *Lactobacillus iners* and *Lactobacillus gasseri* [116-118]. Many types of pathogens for vaginal infections such as; candidal vaginitis, vaginal eubiosis prevention by killing dysbiotic microbes with acidic lactic acid is one of the claims

often made specifically for *lactobacillus* strains probiotics, formulated with multiple or single strains. Such as (*Lactobacillus plantarum*, *Lactobacillus fermentum*, *Lactobacillus rhamnosus* GR-1, *Lactobacillus reuteri* RC-14, *Lactobacillus acidophilus*, *L. brevis*, *L. gasseri*, *L. crispatus*;) such as establishment of vaginal eubiosis by killing dysbiotic microbes, and many types of pathogens, with acidic lactic acid, have been evaluated in several randomized clinical trials that it can prevent vaginal infections, alone or as adjuncts to antibiotic therapy, and for the prevention of bacterial vaginosis [119-122].

Prevention and management of nematodes

One study assessed some aspect of the currently characterization of *Lactobacillus* strains belonging to *Lactobacillus delbrueckii* sub species *bulgaricus* and *lactis* demonstrated that *L. delbrueckii* subsp. *bulgaricus* in diet exerted advantageous effects on nematodes, both *L. delbrueckii* subsp. *lactis* strains affected lifespan and larval development of nematodes, galactose metabolic capabilities and *L. delbrueckii* subspecies *bulgaricus* strain confirmed promising probiotic features [52]. Treatment with *Lactobacillus rhamnosus* JB-1 strain significantly enhanced worm expulsion in resistant C57BL/6 mice, and this was associated with increases in goblet cell numbers, IL-10 levels, and epithelial cell proliferation [52].

Prevention and management of allergy

One study assessed some aspect of the consequence of *Lactobacillus reuteri* in opposition to food allergy was examined in ovalbumin (OVA)-sensitized BALB/c mice study. It was demonstrated that *Lactobacillus reuteri* possesses anti-allergic activities by means of promoting tolerogenic immune responses, modulating enteric flora, as a result worsen profile of enteric flora, and attenuated allergic diarrhea was re-established by *Lactobacillus reuteri* also supplementing infant with *Lactobacillus rhamnosus* GG offered as management of cow milk allergy [123].

Lactobacillus species as recombinant strain, elicit specific mucosal and systemic immune responses

Recombinant probiotics can act as a vaccine arming the host immune system to deal with pathogens. To develop a safe, effective, and convenient vaccine for the prevention of pathogenic, and metabolic problem require to construct recombinant lactic acid bacteria such as *lactobacillus* strains that can express the foreign virus protein, bacteria or cell antigen hence trigger the mucosal and systemic immune responses. Many experimental and clinical studies of *Lactobacillus* strains as probiotic have reported that had an impact on an effective immune response to a specific antigen because a variety of antigens have been expressed in *Lactobacillus* strains.

Recombinant *Lactobacillus* strains are known to elicit specific mucosal and systemic immune responses against antigens recent studies demonstrated that lactic acid is a major antimicrobial factor produced by *Lactobacillus* species such as: Recombinant *Lactobacillus plantarum* studies The study by [124] about assessment of recombinant *Lactobacillus plantarum* expressing SO7 of Eimeria tenella fusion DC-targeting peptide were significantly reduce pathological damage in cecum in broiler chickens, that means could become a hopeful oral vaccine candidate against *E. tenella* infection [22,35,125,126].

The study of Immunogenicity in mice showed higher numbers of CD11c+, CD3+, CD4+, CD3+,CD8+ and interferon gamma- and tumor necrosis factor alpha-expressing spleen lymphocytes in mice

immunize with recombinant *Lactobacillus plantarum* NC8 Expressing Goose Parvovirus VP2 Gene than those in the control groups [32]. A recombinant *Lactobacillus plantarum* NC8 strain expressing NP-M1-DCpep from H9N2 AIV has been studied in a mouse model and exhibited significantly increased T cell-mediated immune responses and mucosal sIgA and IgG levels, which provided protection against H9N2 AIV challenge, in additional intranasal administration induced stronger immune responses and provided effective protection against challenge with the H9N2 virus and *L. plantarum* vaccine vector expressing hemagglutinin provided protection against H9N2 challenge infection [34].

Recombinant *L. plantarum* expressing 3M2e-Fc elicited Peyer's patch (PP) DC activation, improved the number of gamma interferon (IFN- γ)-producing T cells and increased the frequency of CD8+IFN- γ + cells in the mesenteric lymph nodes and enhanced specific sIgA secretion [34].

Recombinant *Lactobacillus plantarum* with surface displayed hemagglutinin subunit 2 (HA2) alone or together with heat-labile toxin B subunit (LTB) from enterotoxigenic *Escherichia coli* in Balb/c mice increased the percentages of B220⁺ IgA⁺ B cells in peyer patch, in consistent with elevated production of mucosal SIgA antibody determined by ELISA [31]. Other *Lactobacillus* species that have been studied for recombinant are: Recombinant *Lactobacillus plantarum* ULAG11 strain was transformed with pLuc2 in millet seed [127], Recombinant *Lactobacillus rhamnosus* and *Lactobacillus fermentum* [128,129].

Administration of recombinant *Lactobacillus casei* expressing F4 (K88) fimbrialadhesinFaeG in conjunction with a heat-labile enterotoxin A (LTAK63) and heat-labile enterotoxin B (LTB) of enterotoxigenic *Escherichia coli* as an oral adjuvant in mice showed significantly higher levels of FaeG-specific serum IgG and mucosal sIgA, as well as the proliferation of lymphocytes [130-132].

***Lactobacillus* species as mucosal delivery vectors for DNA vaccines and therapeutic proteins**

The approach of using live bacterial cells as means of transportations to deliver recombinant antigens has appeared in excess of the past two decades as an interesting option for the improvement of new vaccines. *Lactobacillus* species are known to influence the immune response in a strain-dependent manner; therefore, they are good candidates for developing innovative oral vectors, comprising good options to reduce the strength of pathogens, meant for mucosal delivery approaches [124,130]. Lately, ever-increasing confirmation supported that *Lactobacillus* strains expression systems, through expression and delivery of antigens/adjuvant, are hopeful oral vaccine vectors, due to their: efficient delivery of immunogens to the mucosal inductive locations, exceptional safety, reduced antigen degradation and prevention of protein purification

On the use of *Lactobacillus* species as mucosal delivery vectors for therapeutic proteins and DNA vaccines such as expression signals and host strains, for the heterologous expression of therapeutic proteins such as antigens, cytokines and enzymes [133,134]. Resulting recombinant *Lactobacillus* strains have been tested successfully for their prophylactic and therapeutic effects in different animal models: especially, anti-oxidative *Lactobacillus casei*, *Lactobacillus plantarum* and *Lactobacillus reuteri* strains were constructed and tested in different study models as delivery vehicles for presentation to the mucosa of compounds with pharmaceutical attention, mainly vaccines

[35,124,130,135]. The viability of shuttle vector for heterologous protein expression in *Lactobacillus casei* TISTR1341 was determined that is able to modulate the host response through cloning in pRCEID-LC7.6, the gene encoding the nucleocapsid protein (NP), from the influenza A virus under the control of the homologous promoter from the lactate dehydrogenase gene. *Lactobacillus casei* strains carrying this recombinant plasmid was made known to productively express the NP protein [133]. The study by Lin et al. showed that, recombinant *Lactobacillus acidophilus* (LA-ET) was safe in a cell model and excluded EHEC O157:H7 from LoVo cells at rates of nearly 94 in exclusion and 60% in competition assays. *Lactobacillus acidophilus* induced higher levels of specific mucosal and systemic antibody responses and improved interferon- γ and interleukin-4 and -10 productions, which was coupled with assorted helper T (Th1/Th2) cell responses, and protected against EHEC O157:H7 colonization and infection in mice [134].

This review gave you knowledge to understand the immune system and recent developments in cloning and expression techniques as demonstrating and support the concern of using *Lactobacillus* strains, to develop novel therapeutic protein mucosal delivery vectors which should be tested now in human clinical trials.

Safety concerns of *Lactobacillus* strains

Our study was confirmed that there were no significant adverse events have been demonstrated in the experimental, clinical studies and other controlled trials of *Lactobacillus* species strains because are not expected to degrade host tissue components for example *Lactobacillus rhamnosus* GG; it has been administered to children with chronic inflammatory disease, to adults with inflammatory bowel disease, and to patients with HIV. The administration of *Lactobacillus johnsonii* N6.2 did not modify the Comprehensive metabolic panel (CMP) or complete blood count (CBC) of participants this also important common safety [112]. Combinations of *Lactobacillus rhamnosus* or *Lactobacillus paracasei* with *Bifidobacterium longum* has been used safely from 2 months before delivery until the breastfed infant was 2 months and study of *Lactobacillus Fermentum* CECT5716 as prevention of mastitis in breastfeeding women [136,137]. It is safe when taken by mouth appropriately many studies were orally administered; *Lactobacillus* is also likely safe for women to use inside the vagina [122]. To prevent the reproduction of *Lactobacillus* species in the environment recombinant plasmids and chromosomally-modified bacterial strains can be controlled by the use of auxotrophic mutants. *Lactobacillus* has rarely caused disease in people with weakened immune systems and side effects are usually mild and mainly frequently include intestinal gas.

For these reasons, *Lactobacillus* species has been proven safe both *in vitro* and *in vivo* and are considered as suitable mucosal delivery vectors for heterologous antigens and can be used in clinical trials.

Discussion

Lactobacillus strains as probiotic activate the mucosal immune system through the stimulation of gut antigen presenting cells to promote protection. Different probiotic strains of *Lactobacillus* genera acquire significant and widely acknowledged immunomodulatory properties and health-promoting [35,138]. The approaches leading to the efficient targetness engages the natural ways which do not cause any side effects and assist the body to uphold the immune homeostasis such as the use of probiotics are the ways forward. Different studies

have looked into the prospective mechanisms of action by which *Lactobacillus* strains as probiotics might play a role as primary immune response against pathogens.

More recent studies developed a recombinant *Lactobacillus* strains harbouring proteins or antigens in order to control infections [30,32,34,35,80,125,126]. *Lactobacillus* species based vaccines can regulate immunostimulatory responses and make active antigen presenting cells (APCs), such as macrophages T cells, dendritic cells (DCs) and epithelial cells. DCs are seen as professional APCs that elicit a primary immune response against pathogens challenge [80]. However, several current studies have point out that immunostimulatory function showed tissue-specific differences among DCs in terms of inducing T helper (Th) cell responses [35,130-132] and recommended that *Lactobacillus* species are actively concerned in the improvement of adaptive immune responses by programming many aspects of CD4+ T cell differentiation [80]. In additional many *Lactobacillus* species are microbe-associated molecular pattern (MAMPs) is capable of interacting with epithelial pattern recognition receptors, mainly the Toll-like receptor-2 (TLR2), TLR6 and nod-like receptors which leads to an up-regulation of signaling pathways to modulate the host's immune response [139,140].

In recent years, studies using newly developed technology and analytic methods suggests that *Lactobacillus* species may enhance host defenses and improve vaccine response as a result of the influence of bacteria on host immunity and intestinal integrity against enteric parasites and that *Lactobacillus* strains as probiotics have been extensively studied as a treatment option of various diseases such as: Viral infections in animals and humans, probiotics modulate mucosal immunity, reduced rotavirus binding and infection, and produced antimicrobial peptides with anti-viral activity against rotavirus [33,141,142] cancer [106,143,144] Haemorrhagic cecal Coccidiosis [124], Hypertension [69], obesity [145], diabetes [146], human immunodeficiency virus infection [20], Irritable bowel syndrome [44], fish and shellfish species diseases [147], Fungal infections [148], vaginal health [149].

The administration of microbial metabolites for the prevention and treatment of aberrant immune response is also gaining importance [106,150]. The market size of probiotics has to the highest degree increased consumer anxiety concerning health-promoting effect of nutraceuticals [38,138,151].

Researchers have discovered more specific functions of *Lactobacillus* species in mediating host immunity and immunologic diseases, such as have been revealed to directly down regulate T effector-mediated inflammatory responses as upregulating anti-inflammatory T regulatory cell expression in mice [45,93]. Similarly Wang et al., found that, pretreatment with *Lactobacillus plantarum* L9 to prevent tumour necrosis factor (TNF- α) induced transcellular bacterial translocation and IL-8 production in Caco-2 cells, the researcher demonstrated that it showed the potential to protect enterocytes from an acute inflammatory response and concluded as good potential prophylactic agents in counteracting bacterial translocation, as well in the mixed *Lactobacillus plantarum* group IFN- γ /IL-4 decreased significantly from infection to convalescence but there was significantly higher secretion of sIgA in the intestine of mice [91].

Wen et al., study of *Lactobacillus* GG (LGG) when supplemented in gnotobiotic pigs, with an oral attenuated human rhinovirus(HRV) vaccine found significant strong adjuvant effect and increased mucosal

populations of HRV-specific IFN- γ producing T lymphocytes and oral administration of LGG attenuates an *S. Infantis*-induced increase in the level of serum IL-22, excessive Th1 immune responses and induces the expansion of CD4+T-bet+IFN γ + T cells in peripheral blood, which helps in the eradication of intracellular pathogens [152].

The current studies by Rocha et al., found that nuclear translocation NF- κ B pp65 and TLR2-dependent signaling were increased by treatment with the *Lactobacillus* species (*L. rhamnosus* GG, *L. rhamnosus* KLS, *L. helveticus* IMAU70129, and *L. casei* IMAU60214). This demonstrates that probiotic strains of *Lactobacillus* exert early immunostimulatory effects that may be directly linked to the initial inflammation of the response of human macrophages [98,153]. *Lactobacillus* species such as *Lactobacillus plantarum*, and *Lactobacillus casei* have been shown to increase the expression of proteins involved in tight junction barrier function which induces several protective mechanisms that restore tissue damage, such as modulation of the stability of tight junctions of the gastrointestinal lining because when become compromised and permeability increases, it allows toxins and other forms of waste to leak into the bloodstream then endotoxins trigger immune activation through Toll-like receptor 4 (TLR4) [94,154].

Live *Lactobacillus rhamnosus* GG and UV-inactivated showed that are equally effective in decreasing IL-8 in the intestinal epithelium [98]. Live and heat-killed *Lactobacillus rhamnosus* GG confirmed that are competent to exert comparable effects on the secretion of pro- and anti-inflammatory cytokines and chemokines when included in the diet of infant rats and have reported that these bacteria had an impact on the phagocytic activity of macrophages against extracellular pathogens such as *Lactobacillus acidophilus* ADDIN EN.CITE [155].

Recently, Albarracin et al., Clua et al., Kolling et al., Zelayaand et al., took a different approach studies about *Lactobacillus rhamnosus* and found that induces cytokines which are involved in the immunomodulatory protective effect of HK1505 and PG1505 in the respiratory superinfection: IL-10, IFN- β , and IFN- γ , pointed out that IL-10 involved in the protection against inflammatory damage, while IFN- γ participated in the reduction of pneumococcal growth in the lungs. As well *L. rhamnosus* CRL1505 improved the numbers of CD3+CD4+IFN- γ +, and CD3+CD4+IL-10+ T cells in the lungs of infant mice and IFN- β involved in the protection against lung tissue injury [75,156-158].

Studies by Rene et al., wan et al., Kemgang et al., Jung et al., found that *Lactobacillus* strains induces Th1 mediates cellular immunity and secretion of IFN- γ cytokines, a Th2 response to humoral immunity, and IL-4 secretion which are able to capture intracellular bacteria, viruses, and cancer. *Lactobacillus* strains increase Th1 type IFN- γ cytokine secretion in spleen cells of mice infected with *S. aureus* while reducing the secretion of Th2 type IL-4 cytokines, also revealed that, serum IFN- γ levels were higher in the mice infected with *Lactobacillus* strains compared to mice infected with the control. Some studies have shown that IL-4 is the key to the survival and proliferation of T cells, as IL-4 promotes the production of Th2 cells and excessive IL-4 inhibits the production of IFN- γ . The level of sIgA which inhibits allergenic and pathogenic microorganisms in the intestinal contents of mice treated with *Lactobacillus* strains were significantly higher [45,159-161].

Lactobacillus strains have reported to activate Toll-like receptors (TLR) signaling which induces an increase in the production of proinflammatory cytokines for instance TNF- α , IL-12, and IL-8 which

damage the host beyond the defense against invading pathogens, also increases in the secretion of anti-inflammatory cytokines such as IL-10. *Lactobacillus* strains probiotics and several TLR antagonists have revealed constructive results in the treatment of obesity and other related diseases including diabetes mellitus [57,64,162]

It was also shown that mixed *Lactobacillus plantarum* used as inhibition of *Staphylococcus aureus* by crude and fractionated extract from lactic acid bacteria IFN- γ /IL-4 ratio decreased appreciably from infection to recovery. The secretion of sIgA in the intestine of mice was significantly higher in the mixed *Lactobacillus plantarum* group than in the single lactic acid bacteria group. Treatment with mixed *Lactobacillus* strains increased the anti-inflammatory factor and the secretion of sIgA in the intestine of mice infected with *Staphylococcus aureus* and inhibited inflammation [45,163]. Evaluation of *Lactobacillus coryniformis* CECT5711 strain as a coadjuvant in a vaccination process [16].

Lactobacillus rhamnosus JB-1 strain modulates goblet cell biology and endorses parasite removal via an IL-10-mediated pathway and gives narrative approaching into probiotic effects on innate defense in nematode infection [52]. It was suggested that *Lactobacillus reuteri* as a functional probiotic against food allergy in allergic mice there were production of serum IgE, activation of mast cell, signature T helper (Th) 1 and 2 cytokines; IFN- γ and IL-4. Further it was made known that the intestinal expression of IL-4, IFN- γ , GATA3 and T-bet was down-regulated, improved the expression of IL-10, TGF- β and Foxp3, and the number of IL-10-secreting CD11c+CD103+ mesenteric lymph node (MLN) cells and heat killed *Lactobacillus reuteri* attenuated OVA-induced cell proliferation and IL-2 secretion by MLN cells [123]. Also *Lactobacillus* strains can improve health in the course of many mechanisms/means, to protect the host against potentially pathogenic species that populate the GIT of animals and humans. *Lactobacilli* strains, such as *Lactobacillus acidophilus* LA1, are able to prevent the colonization of the intestine by pathogenic bacteria, such as *Salmonella typhimurium*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*, by antagonistic elimination. *Lactobacillus* strains may protect the host from pathogen invasion by increasing the intestinal epithelial barrier. Some LAB microbe-associated molecular patterns (MAMPs) are able of working together with the Toll-like receptor-2 (TLR2), TLR6 and nod-like receptors [94]. Moreover *Lactobacillus salivarius* JTB07 and *Lactobacillus reuteri* JTB07 have been reported to upregulate the expression of IL-12, IL-8, IL-6, and IL-1, while *Lactobacillus acidophilus* JTB05 to upregulate the interferon-gamma expression level of their host cells [45,158,164]. *Lactobacillus salivarius* UCC 118 and *Lactobacillus johnsonii* LJ-1 were reported to enhance the IgA response and phagocytic activity in head-kidney leucocytes [165].

Many of published research reports have indicated the significance of producing interferon-gamma (IFN- γ), interleukin as well as IgA for treatment of diseases because were repeatedly observed. Development of immunity by *Lactobacillus* strains could associated with lymphoid tissues that regulate the immune response of their hosts for example *Lactobacillus helveticus* R389, *Lactobacillus rhamnosus* HN001 and *Lactobacillus acidophilus* HN017 [97,166-168] have been reported to have the ability to improve the immune system of their host. The mechanism of this improvement is thought to be caused by the consequence of the *Lactobacillus* strains because of the: total serum protein, globulin, interferon-gamma, prostaglandin E production, albumin, tumor necrosis factor, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), and lymphocytes proliferation.

Conclusion and Recommendation

This review has tried to study experimental and clinical studies that are providing a clear understanding of the beneficial *Lactobacillus* strains which have been applied from the year 2015 to 2017. Collectively, the review results support *Lactobacillus* species as probiotics because various *Lactobacillus* strains have proved to be effective and powerful tools for use in human and animal health as antimicrobial against a wide range of potential pathogens and management of metabolic disorders, Vectors expression systems, and immunization strategies have gradually increased the potential use of *Lactobacillus* strains. For this reason, *Lactobacillus* species are considered as a potential replacement of traditional, frequently pathogenic, attenuated microbial transporters. A favorable point of using *Lactobacillus* strains probiotics is the ability to use the mucosal administration, particularly via the universal oral route, which presents several advantages: simplifies vaccine administration, promotes a special type of local immunity and is attractive from the immunological and practical approach, especially for mass vaccination programs in contrast to systemic inoculation. This review sum up and sort out the available information on the application of *Lactobacillus* species as live oral vaccine vectors for induction of immune responses and treatment of pathogenic and metabolic diseases. It constitutes an important source of general information for researchers interested in mucosal vaccine development and constructing *Lactobacillus* strains with vaccine potential. About the safety of *Lactobacillus* strains, the combining of the high immunogenicity vectors with low risk is a proper level of safety, efficacy and providing proper biological control of the recombinant microorganism. Therefore *Lactobacillus* strains can be considered as good candidates for diseases treatment and vaccine development as heterologous protein secretion to date.

Acknowledgement

The financial support by Chinese Government through a grant from the Chinese Government (CSC) (Grant number 201508330278) is highly acknowledged. Also we are thankful to the Jilin Agricultural University for the internet to download Data for this review.

Funding

This study was funded by Chinese Government (CSC) Grant number 201508330278.

Availability of Data and Materials

Not applicable.

Conflict of Interest

Authors declare no conflict of interest.

Consent for Publication

Not applicable

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Authors' Contributions

Shonyela SM searching data and writing first draft. Guan Wang writing second draft, Wentao Yang references writing, Guilian Yang and Chun feng Wang Supervisions and editing last draft of the manuscript.

All authors read and approved the final version of the manuscript.

References

1. Robert L, Labat Robert J (2017) Comments on the history of medical-biological studies of aging, the birth of scientific gerontology. *Current research in translational medicine* 65: 44-47.
2. Nguyen TT, Nguyen HM, Geiger B, Mathiesen G, Eijnsink VG, et al. (2015) Heterologous expression of a recombinant lactobacillal beta-galactosidase in *Lactobacillus plantarum*: effect of different parameters on the sakacin P-based expression system. *Microbial cell factories* 14: 30.
3. Bothe MK, Maathuis AJH, Bellmann S, Van der Vossen J, Berressem D, et al. (2017) Dose-Dependent Prebiotic Effect of Lactulose in a Computer-Controlled In Vitro Model of the Human Large Intestine. *Nutrients* 9: 767.
4. Sugahara H, Yao R, Odamaki T, Xiao JZ (2017) Differences between live and heat-killed bifidobacteria in the regulation of immune function and the intestinal environment. *Beneficial microbes* 8: 463-472.
5. Szatraj K, Szczepankowska AK, Chmielewska Jeznach M (2017) Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts. *Journal of applied microbiology* 123: 325-339.
6. Linares DM, Gomez C, Renes E, Fresno JM, Tornadijo ME, et al. (2017) Lactic Acid Bacteria and Bifidobacteria with Potential to Design Natural Biofunctional Health-Promoting Dairy Foods. *Frontiers in microbiology* 8: 846.
7. Melo TA, Dos Santos TF, Pereira LR, Passos HM, Rezende RP, et al. (2017) Functional Profile Evaluation of *Lactobacillus fermentum* TCUESC01: A New Potential Probiotic Strain Isolated during Cocoa Fermentation 2017: 5165916.
8. Odamaki T, Kato K, Sugahara H, Xiao JZ, Abe F, et al. (2016) Effect of probiotic yoghurt on animal-based diet-induced change in gut microbiota: an open, randomised, parallel-group study. *Beneficial microbes* 7: 473-484.
9. Nuraida L (2015) A review: Health promoting lactic acid bacteria in traditional Indonesian fermented foods. *Food Science and Human Wellness* 4: 47-55.
10. Hadaegh H, Seyyedain Ardabili SM, Tajabadi Ebrahimi M, Chamani M, Azizi Nezhad R (2017) The Impact of Different Lactic Acid Bacteria Sourdoughs on the Quality Characteristics of Toast Bread. *Journal of Food Quality* 2017: 1-11.
11. Reale A, Di Renzo T, Zotta T, Prezioso M, Boscaino F, et al. (2016) Effect of respirative cultures of *Lactobacillus casei* on model sourdough fermentation. *LWT-Food Science and Technology* 73: 622-629.
12. Garcia Mantrana I, Yebra MJ, Haros M, Monedero V (2016) Expression of bifidobacterial phytases in *Lactobacillus casei* and their application in a food model of whole-grain sourdough bread. *International Journal of Food Microbiology* 216: 18-24.
13. Ventimiglia G, Alfonzo A, Galluzzo P, Corona O, Francesca N, et al. (2015) Codominance of *Lactobacillus plantarum* and obligate heterofermentative lactic acid bacteria during sourdough fermentation. *Food microbiology* 51: 57-68.
14. Lee A, Lee YJ, Yoo HJ, Kim M, Chang Y, et al. (2017) Consumption of Dairy Yogurt Containing *Lactobacillus paracasei* ssp. *paracasei*, *Bifidobacterium animalis* ssp. *lactis* and Heat-Treated *Lactobacillus plantarum* Improves Immune Function Including Natural Killer Cell Activity. *Nutrients* 9: 558.
15. Min M, Bunt CR, Mason SL, Bennett GN, Hussain MA (2017) Effect of Non-Dairy Food Matrices on the Survival of Probiotic Bacteria during Storage. *Microorganisms* 5: 43.
16. Redondo N, Nova E, Gheorghe A, Diaz LE, Hernandez A, et al. (2017) Evaluation of *Lactobacillus coryniformis* CECT5711 strain as a coadjuvant in a vaccination process: a randomised clinical trial in healthy adults. *Nutrition & metabolism* 14: 2.
17. Rocha Ramirez LM, Perez Solano RA (2017) Probiotic *Lactobacillus* Strains Stimulate the Inflammatory Response and Activate Human Macrophages. *Journal of Immunology Research* 2017: 4607491.
18. Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, et al. (2017) Influence of diet on the gut microbiome and implications for human health 15: 73.
19. Lim F, Lim S, Ramasamy K (2017) *Pediococcus acidilactici* LAB4 and *Lactobacillus plantarum* LAB12 assimilate cholesterol and modulate ABCA1, CD36, NPC1L1 and SCARB1 in vitro. *Beneficial microbes* 8: 97-109.
20. Lee S, You HJ, Kwon B, Ko G (2017) Complete Genome Sequence of *Lactobacillus jensenii* Strain SNUV360, a Probiotic for Treatment of Bacterial Vaginosis Isolated from the Vagina of a Healthy Korean Woman. *Genome announcements* 5: 1757-1756.
21. Biagioli M, Laghi L, Carino A, Cipriani S, Distrutti E, et al. (2017) Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity. *Frontiers in pharmacology* 8: 505.
22. Toshimitsu T, Ozaki S, Mochizuki J, Furuichi K, Asami Y (2017) Effects of *Lactobacillus plantarum* Strain OLL2712 Culture Conditions on the Anti-inflammatory Activities for Murine Immune Cells and Obese and Type 2 Diabetic Mice. *Applied and environmental microbiology* 83: e03001-16.
23. Saez Lara MJ, Gomez Llorente C, Plaza Diaz J, Gil A (2015) The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. *Bio Med research international* 2015: 505878.
24. Fonseca W, Lucey K, Jang S, Fujimura KE, Rasky A, et al. (2017) *Lactobacillus johnsonii* supplementation attenuates respiratory viral infection via metabolic reprogramming and immune cell modulation. *Mucosal immunology* 2017.
25. Bharwani A, Mian MF, Surette MG, Bienenstock J, Forsythe P (2017) Oral treatment with *Lactobacillus rhamnosus* attenuates behavioural deficits and immune changes in chronic social stress. *BMC medicine* 15: 7.
26. Wang H, Lee IS, Braun C, Enck P (2016) Effect of probiotics on central nervous system functions in animals and humans: a systematic review. *Journal of neurogastroenterology and motility* 22: 589.
27. Sikasunge CS, Johansen MV, Willingham AL, Leifsson PS, Phiri IK (2008) *Taenia solium* porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal antigens after treatment with oxfendazole. *Vet Parasitol* 158: 57-66.
28. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, et al. (2017) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nature Reviews Gastroenterology & Hepatology* 14: 491-502.
29. Yang WT, Yang GL, Wang Q, Huang HB, Jiang YL, et al. (2017) Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by *Lactobacillus plantarum*. *Antiviral research* 138: 9-21.
30. Yang G, Jiang Y, Tong P, Li C, Yang W, et al. (2017) Alleviation of enterotoxigenic *Escherichia coli* challenge by recombinant *Lactobacillus plantarum* expressing a FaeG-and DC-targeting peptide fusion protein. *Beneficial microbes* 8: 379-391.
31. Jiang Y, Yang G, Wang Q, Wang Z, Yang W, et al. (2017) Molecular mechanisms underlying protection against H9N2 influenza virus challenge in mice by recombinant *Lactobacillus plantarum* with surface displayed HA2-LTB. *Journal of Biotechnology* 259: 6-14.
32. Liu YY, Yang WT, Shi SH, Li YJ, Zhao L, et al. (2017) Immunogenicity of recombinant *Lactobacillus plantarum* NC8 expressing goose parvovirus VP2 gene in BALB/c mice. *Journal of Veterinary Science* 18: 159-167.
33. Wang YB, Du W, Fu AK, Zhang XP, Huang Y, et al. (2016) Intestinal microbiota and oral administration of *Enterococcus faecium* associated with the growth performance of new-born piglets. *Beneficial Microbes* 7: 529-538.

34. Shi SH, Yang WT, Yang GL, Zhang XK, Liu YY, et al. (2016) *Lactobacillus plantarum* vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection. *Virus Res* 211: 46-57.
35. Cai R, Jiang Y, Yang W, Yang W, Shi S, et al. (2016) Surface-Displayed IL-10 by Recombinant *Lactobacillus plantarum* Reduces Th1 Responses of RAW264.7 Cells Stimulated with Poly(I:C) or LPS. *Journal of Microbiology and Biotechnology* 26: 421-431.
36. Wang H, Lee IS, Braun C, Enck P (2016) Effect of Probiotics on Central Nervous System Functions in Animals and Humans: A Systematic Review. *Journal of Neurogastroenterology and Motility* 22: 589-605.
37. Suryavanshi MV, Paul D, Doijad SP, Bhute SS, Hingamire TB, et al. (2017) Draft genome sequence of *Lactobacillus plantarum* strains E2C2 and E2C5 isolated from human stool culture. *Standards in Genomic Sciences* 12: 15.
38. Evivie SE, Huo GC, Igene JO, Bian X (2017) Some current applications, limitations and future perspectives of lactic acid bacteria as probiotics. *Food & Nutrition Research* 61: 1318034.
39. Wells JM (2011) Immunomodulatory mechanisms of lactobacilli. *Microbial Cell Factories* 1: S17.
40. Drouault S, Juste C, Marteau P, Renault P, Corthier G (2002) Oral treatment with *Lactococcus lactis* expressing *Staphylococcus hyicus* lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. *Applied and environmental microbiology* 68: 3166-3168.
41. Kang J, Chung WH, Lim TJ, Whon TW, Lim S, et al. (2017) Complete Genome Sequence of *Lactobacillus casei* LC5, a Potential Probiotics for Atopic Dermatitis. *Frontiers in Immunology* 8: 413.
42. Kazou M, Alexandraki V, Pot B, Tsakalidou E, Papadimitriou K (2017) Complete Genome Sequence of the Dairy Isolate *Lactobacillus acidophilus* ACA-DC 1533. *Genome Announcements* 5: 4 e01533-16.
43. Pan L, Zhao PF, Ma XK, Shang QH, Xu YT, et al. (2017) Probiotic supplementation protects weaned pigs against enterotoxigenic *Escherichia coli* K88 challenge and improves performance similar to antibiotics. *Journal of Animal Science* 95: 2627-2639.
44. Wang M, Gao Z, Zhang Y, Pan L (2016) Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option. *Applied microbiology and biotechnology* 100: 5691-5701.
45. Ren D, Gong S, Shu J, Zhu J, Rong F, et al. (2017) Mixed *Lactobacillus plantarum* Strains Inhibit *Staphylococcus aureus* Induced Inflammation and Ameliorate Intestinal Microflora in Mice. *BioMed Research International* 2017: 7476467.
46. Oldak A, Zielinska D (2017) Comparison of Antibacterial Activity of *Lactobacillus plantarum* Strains Isolated from Two Different Kinds of Regional Cheeses from Poland: Oscypek and Korycinski Cheese. *BioMed Research International* 2017: 6820369.
47. Carvalho RD, Breyner N, Menezes Garcia Z, Rodrigues NM, Lemos L, et al. (2017) Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy *Lactococcus lactis* NZ9000 in the prevention of intestinal mucositis. *Microbial Cell Factories* 16: 27.
48. Sebastian Domingo JJ (2017) Review of the role of probiotics in gastrointestinal diseases in adults. *Gastroenterologia y Hepatologia* 40: 417-429.
49. Chang C, Lin H (2016) Dysbiosis in gastrointestinal disorders. *Best Practice & Research Clinical Gastroenterology* 30: 3-15.
50. Antunes MM, Leocadio PC, Teixeira LG, Leonel AJ, Cara DC, et al. (2016) Pretreatment With L-Citrulline Positively Affects the Mucosal Architecture and Permeability of the Small Intestine in a Murine Mucositis Model. *JPEN Journal of Parenteral and Enteral Nutrition* 40: 279-286.
51. Benbouziane B, Ribelles P, Aubry C, Martin R, Kharrat P, et al. (2013) Development of a Stress Inducible Controlled Expression (SICE) system in *Lactococcus lactis* for the production and delivery of therapeutic molecules at mucosal surfaces. *Journal of Biotechnology* 168: 120-129.
52. Zanni E, Schifano E, Motta S, Sciubba F, Palleschi C, et al. (2017) Combination of Metabonomic and Proteomic Analysis Revealed Different Features among *Lactobacillus delbrueckii* Subspecies *bulgaricus* and *lactis* Strains While In Vivo Testing in the Model Organism *Caenorhabditis elegans* Highlighted Probiotic Properties. *Frontiers in Microbiology* 8: 1206.
53. Villena J, Vizoso Pinto MG, Kitazawa H (2016) Intestinal Innate Antiviral Immunity and Immunobiotics: Beneficial Effects against Rotavirus Infection. *Frontiers in Immunology* 7: 563.
54. Chenoll E, Casinos B, Bataller E, Buesa J, Ramon D, et al. (2016) Identification of a Peptide Produced by *Bifidobacterium longum* CECT 7210 with Antiviral Activity. *Frontiers in Microbiology* 7: 655.
55. Vlasova AN, Kandasamy S, Chattha KS, Rajashekar G, Saif LJ (2016) Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus vaccines and infection in different host species. *Veterinary Immunology and Immunopathology* 172: 72-84.
56. Liu H, Hou C, Wang G, Jia H, Yu H, et al. (2017) *Lactobacillus reuteri* I5007 Modulates Intestinal Host Defense Peptide Expression in the Model of IPEC-J2 Cells and Neonatal Piglets. *Nutrients* 9: 559.
57. Olek A, Woynarowski M, Ahren IL, Kierkus J, Socha P, et al. (2017) Efficacy and Safety of *Lactobacillus plantarum* DSM 9843 (LP299V) in the Prevention of Antibiotic-Associated Gastrointestinal Symptoms in Children-Randomized, Double-Blind, Placebo-Controlled Study. *The Journal of Pediatrics* 186: 82-86.
58. Awaad AS, Al Mudharyif HA, Al Othman MR, Zain ME, El Meligy RM (2017) Amhezole, A Novel Fungal Secondary Metabolite from *Aspergillus terreus* for Treatment of Microbial Mouth Infection. *Phytotherapy Research* 31: 395-402.
59. Park MS, Kwon B, Ku S, Ji GE (2017) The Efficacy of *Bifidobacterium longum* BORI and *Lactobacillus acidophilus* AD031 Probiotic Treatment in Infants with Rotavirus Infection. *Nutrients* 9: 887.
60. Bereswill S, Ekmekci I, Escher U, Fiebiger U, Stingl K, et al. (2017) *Lactobacillus johnsonii* ameliorates intestinal, extra-intestinal and systemic pro-inflammatory immune responses following murine *Campylobacter jejuni* infection. *Scientific Reports* 7: 2138.
61. Ballal SA, Veiga P, Fenn K, Michaud M, Kim JH, et al. (2015) Host lysozyme-mediated lysis of *Lactococcus lactis* facilitates delivery of colitis-attenuating superoxide dismutase to inflamed colons. *Proc Natl Acad Sci USA* 112: 7803-7808.
62. Leal JR, Heitman SJ, Conly JM, Henderson EA, Manns BJ (2016) Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of *Clostridium difficile*-Associated Diarrhea in a Provincial Healthcare System. *Infection Control and Hospital Epidemiology* 37: 1079-1086.
63. Golic N, Veljovic K, Popovic N, Djokic J, Strahinic I, et al. (2017) In vitro and in vivo antagonistic activity of new probiotic culture against *Clostridium difficile* and *Clostridium perfringens*. *BMC Microbiology* 17: 108.
64. Mallina R, Craik J, Briffa N, Ahluwalia V, Clarke J, et al. (2017) Probiotic containing *Lactobacillus casei*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus* (ACTMEL) for the prevention of *Clostridium difficile* associated diarrhoea in the elderly with proximal femur fractures. *Journal of Infection and Public Health* 2017.
65. Agnes UEA, Helen II, Veronica JU, Clement MZW, Sunday A, et al. (2014) Assessment of sanitary conditions of unregistered pig slaughter slabs and post mortem examination of pigs for *Taenia solium* metacestodes in Kaduna metropolis, Nigeria. *Infectious Diseases of Poverty* 3: 45.
66. Fernandez MA, Murette A (2017) Potential Health Benefits of Combining Yogurt and Fruits Based on Their Probiotic and Prebiotic Properties. *Advances in Nutrition* 8: 155s-164s.
67. Karaffova V, Csank T, Mudronova D, Kiraly J, Revajova V, et al. (2017) Influence of *Lactobacillus reuteri* L26 Biocenol on immune response against porcine circovirus type 2 infection in germ-free mice. *Beneficial Microbes* 8: 367-378.
68. Weber GJ, Pushpakumar S, Tyagi SC, Sen U (2016) Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension. *Pharmacological Research* 113: 300-312.
69. Yang G, Jiang Y, Yang W, Du F, Yao Y, et al. (2015) Effective treatment of hypertension by recombinant *Lactobacillus plantarum* expressing

- angiotensin converting enzyme inhibitory peptide. *Microbial Cell Factories* 14: 202.
70. Lecomte V, Kaakoush NO, Maloney CA, Raipuria M, Huinao KD, et al. (2015) Changes in gut microbiota in rats fed a high fat diet correlate with obesity-associated metabolic parameters. *PLoS one* 10: e0126931.
71. Al Khodor S, Reichert B, Shatat IF (2017) The Microbiome and Blood Pressure: Can Microbes Regulate Our Blood Pressure? *Frontiers in Pediatrics* 5: 138.
72. Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, et al. (2016) Role of the Gut Microbiome in Obstructive Sleep Apnea-Induced Hypertension. *Hypertension* 67: 469-474.
73. Karbach SH, Schonfelder T, Brandao I, Wilms E, Hormann N, et al. (2016) Gut Microbiota Promote Angiotensin II-Induced Arterial Hypertension and Vascular Dysfunction. *Journal of the American Heart Association* 5: e003698.
74. Daliri EB, Oh DH, Lee BH (2017) Bioactive Peptides. *Foods* 6.
75. Kolling Y, Salva S, Villena J, Marranzino G, Alvarez S (2015) Non-viable immunobiotic *Lactobacillus rhamnosus* CRL1505 and its peptidoglycan improve systemic and respiratory innate immune response during recovery of immunocompromised-malnourished mice. *International Immunopharmacology* 25: 474-484.
76. Clua P, Kanmani P, Zelaya H, Tada A, Kober A, et al. (2017) Peptidoglycan from Immunobiotic *Lactobacillus rhamnosus* Improves Resistance of Infant Mice to Respiratory Syncytial Viral Infection and Secondary Pneumococcal Pneumonia. *Frontiers in Immunology* 8: 948.
77. Barbieri N, Herrera M, Salva S, Villena J, Alvarez S (2017) *Lactobacillus rhamnosus* CRL1505 nasal administration improves recovery of T-cell mediated immunity against pneumococcal infection in malnourished mice. *Beneficial Microbes* 8: 393-405.
78. Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, et al. (2017) A randomized synbiotic trial to prevent sepsis among infants in rural India. *Nature* 548: 407-412.
79. Strasser B, Geiger D, Schauer M, Gostner JM, Gatterer H, et al. (2016) Probiotic Supplements Beneficially Affect Tryptophan-Kynurenine Metabolism and Reduce the Incidence of Upper Respiratory Tract Infections in Trained Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial. *Nutrients* 8: 752.
80. Yang WT, Yang GL, Shi SH, Liu YY, Huang HB, et al. (2017) Protection of chickens against H9N2 avian influenza virus challenge with recombinant *Lactobacillus plantarum* expressing conserved antigens. *Applied Microbiology and Biotechnology* 101: 4593-4603.
81. Yang WT, Shi SH, Yang GL, Jiang YL, Zhao L, et al. (2016) Cross-protective efficacy of dendritic cells targeting conserved influenza virus antigen expressed by *Lactobacillus plantarum*. *Scientific Reports* 6: 39665.
82. Kwak W, Kim K, Lee C, Lee C, Kang J, et al. (2016) Comparative Analysis of the Complete Genome of *Lactobacillus plantarum* GB-LP2 and Potential Candidate Genes for Host Immune System Enhancement. *J Microbiol Biotechnol* 26: 684-692.
83. Hayat U, Dugum M, Garg S (2017) Chronic constipation: Update on management. *Cleveland Clinic Journal of Medicine* 84: 397-408.
84. Martinez Martinez MI, Calabuig Tolsa R, Cauli O (2017) The effect of probiotics as a treatment for constipation in elderly people: A systematic review. *Archives of Gerontology and Geriatrics* 71: 142-149.
85. Koppen IJ, Velasco Benitez CA, Benninga MA, Di Lorenzo C, Saps M (2016) Using the Bristol Stool Scale and Parental Report of Stool Consistency as Part of the Rome III Criteria for Functional Constipation in Infants and Toddlers. *The Journal of Pediatrics* 177: 44-48.
86. Zhao Y, Yu YB (2016) *Intestinal Microbiota and Chronic Constipation*. Springer Plus 5: 1130.
87. Wojtyniak K, Horvath A, Dziechciarz P, Szajewska H () *Lactobacillus casei rhamnosus* Lcr35 in the Management of Functional Constipation in Children: A Randomized Trial. *The Journal of Pediatrics* 184: 101-105.e101.
88. Lim SM, Jang HM, Jang SE, Han MJ, Kim DH (2017) *Lactobacillus fermentum* IM12 attenuates inflammation in mice by inhibiting NF-kappaB-STAT3 signalling pathway. *Beneficial Microbes* 8: 407-419.
89. Michael DR, Davies TS, Moss JWE, Calvente DL, Ramji DP, et al. (2017) The anti-cholesterolaemic effect of a consortium of probiotics: An acute study in C57BL/6J mice. *Scientific Reports* 7: 2883.
90. Tomaro Duchesneau C, Saha S, Malhotra M, Jones ML, Rodes L, et al. (2015) *Lactobacillus fermentum* NCIMB 5221 and NCIMB 2797 as cholesterol-lowering probiotic biotherapeutics: in vitro analysis. *Beneficial Microbes* 6: 861-869.
91. Wang B, Chen J, Wang S, Zhao X, Lu G, et al. (2017) *Lactobacillus plantarum* L9 but not *Lactobacillus acidophilus* LA reduces tumour necrosis factor induced bacterial translocation in Caco-2 cells. *Beneficial Microbes* 8: 497-505.
92. Mencarelli A, Cipriani S, Francisci D, Santucci L, Baldelli F, et al. (2016) Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. *Scientific Reports* 6: 30802.
93. Neurath MF (2017) Current and emerging therapeutic targets for IBD. *Nature reviews Gastroenterology & hepatology* 14: 269-278.
94. Ren C, Zhang Q, De Haan BJ, Zhang H, Faas MM, et al. (2016) Identification of TLR2/TLR6 signalling lactic acid bacteria for supporting immune regulation. *Scientific Reports* 6: 34561.
95. De Souza HS, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. *Nature Reviews Gastroenterology & Hepatology* 13: 13-27.
96. Neyrinck AM, Etxeberria U, Taminiau B, Daube G, Van Hul M, et al. (2017) Rhubarb extract prevents hepatic inflammation induced by acute alcohol intake, an effect related to the modulation of the gut microbiota. *Molecular Nutrition & Food Research* 61: 1500899.
97. Chen Z, Shi J, Yang X, Nan B, Liu Y, et al. (2015) Chemical and physical characteristics and antioxidant activities of the exopolysaccharide produced by Tibetan kefir grains during milk fermentation. *International Dairy Journal* 43: 15-21.
98. Rocha Ramirez LM, Hernandez Chinas U, Banos Rojas D, Xicohtencatl Cortes J, Chavez Berrocal ME, et al. (2016) Pet serine protease from enteroaggregative *Escherichia coli* stimulates the inflammatory response activating human macrophages. *BMC Microbiology* 16: 158.
99. Lascrain L, Jensen MK, Guthery SL, Holmen J, Deneau M (2016) Inflammatory Bowel Disease Phenotype in Pediatric Primary Sclerosing Cholangitis. *Inflammatory Bowel Diseases* 22: 146-150.
100. Azcarate Peril MA, Ritter AJ, Savaiano D, Monteagudo Mera A, Anderson C, et al. (2017) Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals. *Proceedings of the National Academy of Sciences of the United States of America* 114: E367-e375.
101. Zubiria MG, Gambaro SE, Rey MA, Carasi P, Serradell MLA, et al. (2017) Deleterious Metabolic Effects of High Fructose Intake: The Preventive Effect of *Lactobacillus kefir* Administration. *Nutrients* 9: 470.
102. Riaz Rajoka MS, Shi J, Zhu J, Shao D, Huang Q, et al. (2017) Capacity of lactic acid bacteria in immunity enhancement and cancer prevention. *Applied Microbiology and Biotechnology* 101: 35-45.
103. Kahouli I, Malhotra M, Westfall S, Alaoui Jamali M, Prakash S (2017) The potential of *Lactobacillus* probiotic treatments in colorectal cancer (CRC). *Cancer Research* 77: 254.
104. Lenoir M, Del Carmen S, Cortes Perez NG, Lozano Ojalvo D, Munoz Provencio D, et al. (2016) *Lactobacillus casei* BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. *Journal of Gastroenterology* 51: 862-873.
105. So SS, Wan ML, El Nezami H (2017) Probiotics-mediated suppression of cancer. *Current Opinion in Oncology* 29: 62-72.
106. Chen X, Zhao X, Wang H, Yang Z, Li J, (2017) Prevent Effects of *Lactobacillus Fermentum* HY01 on Dextran Sulfate Sodium-Induced Colitis in Mice. *Nutrients* 9: 545.

107. Afonso SM, Vaz Y, Neves L, Pondja A, Dias G, et al. (2011) Human and porcine *Taenia solium* infections in Mozambique: identifying research priorities. *Animal Health Research Reviews* 12: 123-129.
108. Biu AA, Ijudai J (2012) Prevalence and morphometric studies on porcine cysticercosis in Adamawa state, Nigeria. *Sokoto J of Vet Sci* 10: 1-5.
109. Liao T, Chen YP, Huang SQ, Tan LL, Li CQ, et al. (2017) Chondroitin sulfate elicits systemic pathogenesis in mice by interfering with gut microbiota homeostasis. *The Preprint Server for Biology* 10: 1-5.
110. Jonsson AL, Backhed F (2017) Role of gut microbiota in atherosclerosis. *Nat Rev Cardiol* 14: 79-87.
111. Ma S, We L, Yang H, Deng S, Jevnikar A (2017) Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM). *Canadian Journal of Biotechnology* 1: 1-5.
112. Marcial GE, Ford AL, Haller MJ, Gezan SA, Harrison NA, et al. (2017) *Lactobacillus johnsonii* N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults. *Frontiers in immunology* 8: 655.
113. Tiequn B, Guanqun C, Shuo Z (2015) Therapeutic effects of *Lactobacillus* in treating irritable bowel syndrome: a meta-analysis. *Internal Medicine* 54: 243-249.
114. Zhang Y, Li L, Guo C, Mu D, Feng B, et al. (2016) Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. *BMC Gastroenterology* 16: 62.
115. Weaver KR, Melkus GD, Henderson WA (2017) Irritable Bowel Syndrome. *The American journal of nursing* 117: 48-55.
116. Nasioudis D, Beghini J, Bongiovanni AM, Giraldo PC, Linhares IM, et al. (2016) Alpha Amylase in Vaginal Fluid: Association With Conditions Favorable to Dominance of *Lactobacillus*. *Reproductive sciences* 22: 1393-1398.
117. Mirmonsef P, Modur S, Burgad D, Gilbert D, Golub ET, et al. (2015) Exploratory comparison of vaginal glycogen and *Lactobacillus* levels in premenopausal and postmenopausal women. *Menopause* 22: 702-709.
118. Tomusiak A, Strus M, Heczko PB, Adamski P, Stefanski G, et al. (2015) Efficacy and safety of a vaginal medicinal product containing three strains of probiotic bacteria: a multicenter, randomized, double-blind, and placebo-controlled trial. *Drug Design, Development and Therapy* 9: 5345-5354.
119. Recine N, Palma E, Domenici L, Giorgini M, Imperiale L, et al. (2016) Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using *Lactobacillus rhamnosus* BMX 54 as adjuvant treatment against bacterial vaginosis. *Archives of Gynecology and Obstetrics* 29: 101-107.
120. Hutt P, Lapp E, Stsepetova J, Smidt I, Taelma H, et al. (2016) Characterisation of probiotic properties in human vaginal lactobacilli strains. *Microbial Ecology in Health and Disease* 27: 30484.
121. Klatt NR, Cheu R, Birse K (2017) Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. *Science* 356: 938-945.
122. Velloza J, Heffron R (2017) The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women. *Current HIV/AIDS reports* 2017.
123. Huang CH, Lin YC, Jan TR (2017) *Lactobacillus reuteri* induces intestinal immune tolerance against food allergy in mice. *Journal of Functional Foods* 31: 44-51.
124. Yang G, Yao J, Yang W, Jiang Y, Du J, et al. (2017) Construction and immunological evaluation of recombinant *Lactobacillus plantarum* expressing SO7 of *Eimeria tenella* fusion DC-targeting peptide. *Vet Parasitol* 236: 7-13.
125. Toshimitsu T, Mochizuki J, Ikegami S, Itou H (2016) Identification of a *Lactobacillus plantarum* strain that ameliorates chronic inflammation and metabolic disorders in obese and type 2 diabetic mice. *Journal of Dairy Science* 99: 933-946.
126. Wang B, Chen J, Wang S, Zhao X, Lu G, et al. (2017) *Lactobacillus plantarum* L9 but not *Lactobacillus acidophilus* LA reduces tumour necrosis factor induced bacterial translocation in Caco-2 cells. *Beneficial Microbes* 8: 497-505.
127. Moon GS, Narbad A (2017) Monitoring of Bioluminescent *Lactobacillus plantarum* in a Complex Food Matrix. *Korean Journal for Food Science of Animal Resources* 37: 147-152.
128. Jiang Y, Yang G, Meng F, Yang W, Hu J, et al. (2016) Immunological mechanisms involved in probiotic-mediated protection against *Citrobacter rodentium*-induced colitis. *Beneficial Microbes* 7: 397-407.
129. Jiang Y, Ye L, Cui Y, Yang G, Yang W, et al. (2017) Effects of *Lactobacillus rhamnosus* GG on the maturation and differentiation of dendritic cells in rotavirus-infected mice. *Beneficial Microbes* 8: 645-656.
130. Yu M, Qi R, Chen C, Yin J, Ma S, et al. (2017) Immunogenicity of recombinant *Lactobacillus casei*-expressing F4 (K88) fimbrial adhesin FaeG in conjunction with a heat-labile enterotoxin A (LTAK63) and heat-labile enterotoxin B (LTB) of enterotoxigenic *Escherichia coli* as an oral adjuvant in mice. *Journal of Applied Microbiology* 122: 506-515.
131. Li X, Wang E, Yin B, Fang D, Chen P, et al. (2017) Effects of *Lactobacillus casei* CCFM419 on insulin resistance and gut microbiota in type 2 diabetic mice. *Beneficial Microbes* 8: 421-432.
132. Cortes Perez NG, Lozano Ojalvo D, Maiga MA, Hazebrouck S, Adel Patient K (2017) Intra-gastric administration of *Lactobacillus casei* BL23 induces regulatory FoxP3+RORgammat+ T cells subset in mice. *Beneficial Microbes* 8: 433-438.
133. Suebwongsa N, Lulitanond V, Mayo B, Yotpanya P, Panya M (2016) Development of an *Escherichia coli*-*Lactobacillus casei* shuttle vector for heterologous protein expression in *Lactobacillus casei*. *Springer Plus* 5: 169.
134. Lin R, Zhang Y, Long B, Li Y, Wu Y, et al. (2017) Oral Immunization with Recombinant *Lactobacillus acidophilus* Expressing espA-Tir-M Confers Protection against Enterohemorrhagic *Escherichia coli* O157:H7 Challenge in Mice. *Frontiers in Microbiology* 8: 417.
135. Yang WC, Hsu TC, Cheng KC, Liu JR (2017) Expression of the *Clonostachys rosea* lactonohydrolase gene by *Lactobacillus reuteri* to increase its zearalenone removing ability. *Microbial Cell Factories* 16: 69.
136. Neuman H, Koren O (2017) The Pregnancy Microbiome. *Nestle Nutrition Institute Workshop Series* 88: 1-9.
137. Bond DM, Morris JM, Nassar N (2017) Study protocol: evaluation of the probiotic *Lactobacillus Fermentum* CECT5716 for the prevention of mastitis in breastfeeding women: a randomised controlled trial. *BMC Pregnancy and Childbirth* 17: 148.
138. Fabersani E, Abejion Mukdsi MC, Ross R, Medina R, Gonzalez S, et al. (2017) Specific Strains of Lactic Acid Bacteria Differentially Modulate the Profile of Adipokines In Vitro. *Frontiers in Immunology* 8: 266.
139. Miura K, Ishioka M, Iijima K (2017) The Roles of the Gut Microbiota and Toll-like Receptors in Obesity and Nonalcoholic Fatty Liver Disease. *Journal of Obesity & Metabolic Syndrome* 26: 86-96.
140. Zhang Z, Zhou Z, Li Y, Zhou L, Ding Q, et al. (2016) Isolated exopolysaccharides from *Lactobacillus rhamnosus* GG alleviated adipogenesis mediated by TLR2 in mice. *Scientific Reports* 6: 36083.
141. Olaya Galan NN, Ulloa Rubiano JC, Velez Reyes FA, Fernandez Duarte KP, Salas Cardenas SP, et al. (2016) In vitro antiviral activity of *Lactobacillus casei* and *Bifidobacterium adolescentis* against rotavirus infection monitored by NSP4 protein production. *Journal of applied microbiology* 120: 1041-1051.
142. Kandasamy S, Vlasova AN, Fischer DD, Chattha KS, Shao L, et al. (2017) Unraveling the Differences between Gram-Positive and Gram-Negative Probiotics in Modulating Protective Immunity to Enteric Infections. *Frontiers in Immunology* 8: 334.
143. Gabriel S, Dorny P, Mwape KE, Trevisan C, Braae UC, et al. (2017) Control of *Taenia solium* taeniasis/cysticercosis: The best way forward for sub-Saharan Africa? *Acta Tropica* 165: 252-260.
144. Mwape KE, Phiri IK, Praet N, Muma JB, Zulu G, et al. (2012) *Taenia solium* infections in a rural area of Eastern Zambia- a community based study. *PLoS Negl Trop Dis* 6: e1594.
145. Novotny Nunez I, Maldonado Galdeano C, De Moreno de LeBlanc A, Perdigon G (2015) *Lactobacillus casei* CRL 431 administration decreases inflammatory cytokines in a diet-induced obese mouse model. *Nutrition* 31: 1000-1007.

146. Lindsay KL, Brennan L, Kennelly MA, Maguire OC, Smith T, et al. (2015) Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 212: e491-e411.
147. Martínez Porchas M, Vargas Albores F (2017) Microbial metagenomics in aquaculture: a potential tool for a deeper insight into the activity. *Reviews in Aquaculture* 9: 42-56.
148. Ward TL, Knights D, Gale CA (2017) Infant fungal communities: current knowledge and research opportunities. *BMC Medicine* 15: 30.
149. Tachedjian G, Aldunate M, Bradshaw CS, Cone RA (2017) The role of lactic acid production by probiotic *Lactobacillus* species in vaginal health. *Research in Microbiology*.
150. Terán V, Pizarro PL, Zacarías MF, Vinderola G, Medina R, et al. (2015) Production of conjugated dienoic and trienoic fatty acids by lactic acid bacteria and bifidobacteria. *Journal of Functional Foods* 19: 417-425.
151. Augustin MA, Sanguansri L (2015) Challenges and solutions to incorporation of nutraceuticals in foods. *Annual review of food science and technology* 6: 463-477.
152. Wen K, Liu F, Li G, Bai M, Kocher J, et al. (2015) *Lactobacillus rhamnosus* GG Dosage Affects the Adjuvanticity and Protection Against Rotavirus Diarrhea in Gnotobiotic Pigs. *Journal of Pediatric Gastroenterology and Nutrition* 60: 834-843.
153. Rocha Ramírez LM, Pérez Solano RA, Castañón Alonso SL, Moreno Guerrero SS, Ramírez Pacheco A, et al. (2017) Probiotic *Lactobacillus* Strains Stimulate the Inflammatory Response and Activate Human Macrophages. *Journal of Immunology Research* 2017: 14.
154. Bajaj BK, Claes IJJ, Lebeer S (2015) Functional mechanisms of probiotics. *Journal of Microbiology, Biotechnology and Food Sciences* 04: 321-327.
155. Rocha Ramírez LM, Perez Solano RA, Castanon Alonso SL, Moreno Guerrero SS, Ramirez Pacheco A, et al. (2017) Probiotic *Lactobacillus* Strains Stimulate the Inflammatory Response and Activate Human Macrophages. *Journal of Immunology Research* 2017: 4607491.
156. Zelaya H, Tada A, Vizoso Pinto MG, Salva S, Kanmani P, et al. (2015) Nasal priming with immunobiotic *Lactobacillus rhamnosus* modulates inflammation-coagulation interactions and reduces influenza virus-associated pulmonary damage. *Inflammation Research* 64: 589-602.
157. Albarracín L, Kobayashi H, Iida H, Sato N, Nochi T, et al. (2017) Transcriptomic Analysis of the Innate Antiviral Immune Response in Porcine Intestinal Epithelial Cells: Influence of Immunobiotic *Lactobacilli*. *Frontiers in Immunology* 8: 57.
158. Clua P, Kanmani P, Zelaya H, Tada A, Kober AKMH, et al. (2017) Peptidoglycan from Immunobiotic *Lactobacillus rhamnosus* Improves Resistance of Infant Mice to Respiratory Syncytial Viral Infection and Secondary Pneumococcal Pneumonia. *Frontiers in Immunology*.
159. Jung JY, Shin JS, Lee SG, Rhee YK, Cho CW, et al. (2015) *Lactobacillus sakei* K040706 evokes immunostimulatory effects on macrophages through TLR 2-mediated activation. *International immunopharmacology* 28: 88-96.
160. Kemgang TS, Kapila S, Shamugam VP, Reddi S, Kapila R (2016) Fermented milk with probiotic *Lactobacillus rhamnosus* S1K3 (MTCC5957) protects mice from salmonella by enhancing immune and nonimmune protection mechanisms at intestinal mucosal level. *The Journal of Nutritional Biochemistry* 30: 62-73.
161. Wan MLY, Turner PC, Allen KJ, El Nezami H (2016) *Lactobacillus rhamnosus* GG modulates intestinal mucosal barrier and inflammation in mice following combined dietary exposure to deoxynivalenol and zearalenone. *Journal of Functional Foods* 22: 34-4s3.
162. Fernandez MA, Marette A (2017) Potential Health Benefits of Combining Yogurt and Fruits Based on Their Probiotic and Prebiotic Properties. *Advances in Nutrition* 8: 155S-164S.
163. Wong CB, Khoo BY, Sasidharan S, Piyawattanametha W, Kim SH, et al. (2015) Inhibition of *Staphylococcus aureus* by crude and fractionated extract from lactic acid bacteria. *Beneficial microbes* 6: 129-139.
164. Quinteiro Filho WM, Brisbin JT, Hodgins DC, Sharif S (2015) *Lactobacillus* and *Lactobacillus* cell-free culture supernatants modulate chicken macrophage activities. *Research in Veterinary Science* 103: 170-175.
165. Munoz Atienza E, Araujo C, Lluich N, Hernandez PE, Herranz C, et al. (2015) Different impact of heat-inactivated and viable lactic acid bacteria of aquatic origin on turbot (*Scophthalmus maximus* L.) head-kidney leucocytes. *Fish & Shellfish Immunology* 44: 214-223.
166. Hoseinifar SH, Roosta Z, Hajimoradloo A, Vakili F (2015) The effects of *Lactobacillus acidophilus* as feed supplement on skin mucosal immune parameters, intestinal microbiota, stress resistance and growth performance of black swordtail (*Xiphophorus helleri*). *Fish & Shellfish Immunology* 42: 533-538.
167. Inic Kanada A, Stojanovic M, Marinkovic E, Becker E, Stein E, et al. (2016) A Probiotic Adjuvant *Lactobacillus rhamnosus* Enhances Specific Immune Responses after Ocular Mucosal Immunization with Chlamydial Polymorphic Membrane Protein C. *PLoS one* 11: e0157875.
168. Kandasamy S, Vlasova AN, Fischer D, Kumar A, Chattha KS, et al. (2016) Differential Effects of *Escherichia coli* Nissle and *Lactobacillus rhamnosus* Strain GG on Human Rotavirus Binding, Infection, and B Cell Immunity. *Journal of Immunology* 196: 1780-1789.